THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Misty Oldham

Concepts (69)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Sofosbuvir
1
2017
1
0.570
Why?
Carbamates
1
2017
5
0.570
Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
11
0.570
Why?
Hepatitis C, Chronic
1
2017
30
0.560
Why?
Antiviral Agents
1
2017
111
0.530
Why?
Genotype
1
2017
444
0.520
Why?
Judgment
1
2021
30
0.380
Why?
Education, Pharmacy
1
2021
108
0.330
Why?
Education, Pharmacy, Graduate
1
2018
17
0.300
Why?
Aminoglycosides
1
2014
10
0.240
Why?
Hyperphosphatemia
1
2014
4
0.240
Why?
Amphotericin B
1
2014
17
0.230
Why?
HIV Integrase Inhibitors
1
2013
2
0.220
Why?
Heterocyclic Compounds, 3-Ring
1
2013
3
0.220
Why?
Antifungal Agents
1
2014
59
0.220
Why?
Drug Combinations
2
2017
50
0.200
Why?
HIV Infections
1
2013
149
0.190
Why?
Tablets
1
2017
6
0.140
Why?
Clinical Trials, Phase III as Topic
1
2017
19
0.140
Why?
Humans
6
2021
27180
0.110
Why?
Assertiveness
1
2021
4
0.100
Why?
Empathy
1
2021
36
0.090
Why?
Infant, Newborn
2
2014
851
0.090
Why?
Treatment Outcome
1
2017
2288
0.090
Why?
Communication
1
2021
170
0.080
Why?
Occupations
1
2018
9
0.080
Why?
Writing
1
2018
14
0.080
Why?
Feedback
1
2018
32
0.080
Why?
Education
1
2018
33
0.080
Why?
Educational Measurement
1
2018
125
0.070
Why?
Learning
1
2018
96
0.070
Why?
Students, Pharmacy
1
2018
78
0.070
Why?
Curriculum
1
2018
271
0.070
Why?
Follow-Up Studies
1
2018
990
0.060
Why?
Amikacin
1
2014
4
0.060
Why?
Cross-Sectional Studies
1
2018
937
0.060
Why?
Gentamicins
1
2014
15
0.060
Why?
Delayed-Action Preparations
1
2014
39
0.060
Why?
Tobramycin
1
2014
13
0.060
Why?
Phosphorus
1
2014
51
0.060
Why?
Drug Administration Schedule
1
2014
218
0.060
Why?
Raltegravir Potassium
1
2013
1
0.060
Why?
Cyclopropanes
1
2013
4
0.060
Why?
Pyrrolidinones
1
2013
3
0.060
Why?
Benzoxazines
1
2013
3
0.060
Why?
Reverse Transcriptase Inhibitors
1
2013
8
0.060
Why?
Half-Life
1
2013
32
0.060
Why?
Alkynes
1
2013
7
0.060
Why?
Ritonavir
1
2013
11
0.060
Why?
HIV Protease Inhibitors
1
2013
14
0.060
Why?
Oxazines
1
2013
18
0.050
Why?
Pyridones
1
2013
33
0.050
Why?
Drug Interactions
1
2013
77
0.050
Why?
Animals
1
2017
10082
0.050
Why?
Piperazines
1
2013
45
0.050
Why?
Practice Guidelines as Topic
1
2014
235
0.050
Why?
Dose-Response Relationship, Drug
1
2014
591
0.050
Why?
Clinical Trials as Topic
1
2013
206
0.050
Why?
Young Adult
1
2018
2636
0.050
Why?
Male
2
2018
13035
0.050
Why?
Infant
1
2014
973
0.050
Why?
Child, Preschool
1
2014
1103
0.040
Why?
Anti-Bacterial Agents
1
2014
498
0.040
Why?
Female
2
2018
14658
0.040
Why?
Risk Factors
1
2014
2043
0.040
Why?
Child
1
2014
2169
0.040
Why?
Retrospective Studies
1
2014
2467
0.040
Why?
Adolescent
1
2014
3000
0.030
Why?
Adult
1
2018
7510
0.030
Why?
Oldham's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (69)
Explore
_
Co-Authors (5)
Explore
_
Similar People (56)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES